Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

Revenues for GLAND are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 4.335000
forwardPE 22.520443
debtToEquity 3.428000
earningsGrowth -0.031000
revenueGrowth -0.073000
grossMargins 0.592360
operatingMargins 0.176680
trailingEps 42.730000
forwardEps 65.010000

With a current ratio of 4.335, GLAND has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that GLAND is in a strong position to meet its immediate financial obligations without difficulty.
GLAND's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
GLAND's low earnings and revenue growth point to a possible reduction in profits. This trend suggests that the company may face difficulties in maintaining its profitability and could be a cause for concern among investors.
GLAND's negative gross and operating margins highlight that the company is incurring losses, unable to generate profit from production or operations. This could be a sign of rising costs or declining revenues, impacting its financial outlook.
Gland Pharma Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Gland Pharma Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for GLAND
Price projections for GLAND

GLAND's price projections have been revised downward gradually, indicating that analysts are tempering their expectations. This downward shift suggests a more cautious outlook on the company's growth prospects.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


Gland Pharma Limited experienced 9 sell transactions with market price of 1839.5444471571182 per share.No sell transactions took place in the period under consideration.The recent trend of more purchases than sales at GLAND's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


The recent sell bias from analysts toward Gland Pharma Limited suggests investors should exercise caution. Instead of acting on this bias alone, it's important to evaluate a broader range of market indicators to make more balanced and informed decisions regarding the stock's future prospects.